Karyopharm Therapeutics Inc (KPTI) - Total Liabilities

Latest as of December 2025: $401.34 Million USD

Based on the latest financial reports, Karyopharm Therapeutics Inc (KPTI) has total liabilities worth $401.34 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Karyopharm Therapeutics Inc equity growth rate to track the company's year-over-year net asset growth rate.

Karyopharm Therapeutics Inc - Total Liabilities Trend (2011–2025)

This chart illustrates how Karyopharm Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Karyopharm Therapeutics Inc to measure how efficiently the company converts operating cash flow to free cash.

Karyopharm Therapeutics Inc Competitors by Total Liabilities

The table below lists competitors of Karyopharm Therapeutics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Surapon Foods Public Company Limited BK:SSF	Thailand	฿1.38 Billion
Mirae Asset Global REIT Co. Ltd. KO:396690	Korea	₩209.78 Billion
HPQ SILICON INC. F:O08	Germany	€3.34 Million
Arianne Phosphate Inc V:DAN	Canada	CA$46.27 Million
Woongjin Thinkbig Co Ltd KO:095720	Korea	₩469.93 Billion
Sangsangin Ian No.1 Special Purpose Acquisition Co. Ltd KQ:307870	Korea	₩29.02 Billion
Union Petrochemical Public Company Limited BK:UKEM	Thailand	฿943.43 Million

Liability Composition Analysis (2011–2025)

This chart breaks down Karyopharm Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Karyopharm Therapeutics Inc stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.12	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-1.37	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	3.70	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Karyopharm Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Karyopharm Therapeutics Inc (2011–2025)

The table below shows the annual total liabilities of Karyopharm Therapeutics Inc from 2011 to 2025.

Year	Total Liabilities	Change
2025-12-31	$401.34 Million	+14.53%
2024-12-31	$350.44 Million	-6.96%
2023-12-31	$376.64 Million	+0.48%
2022-12-31	$374.83 Million	-2.64%
2021-12-31	$384.98 Million	+46.66%
2020-12-31	$262.50 Million	+7.06%
2019-12-31	$245.19 Million	+55.16%
2018-12-31	$158.02 Million	+210.88%
2017-12-31	$50.83 Million	+180.18%
2016-12-31	$18.14 Million	+6.23%
2015-12-31	$17.08 Million	+26.10%
2014-12-31	$13.54 Million	+311.39%
2013-12-31	$3.29 Million	-88.72%
2012-12-31	$29.19 Million	+46.86%
2011-12-31	$19.88 Million	--

About Karyopharm Therapeutics Inc

NASDAQ:KPTI USA Biotechnology

Market Cap

$43.30 Million

Market Cap Rank

#22372 Global

#4888 in USA

Share Price

$1.92

Change (1 day)

-72.61%

52-Week Range

$1.92 - $10.67

All Time High

$27.72